Newsroom

Industry News

20 Jan

Actinium Announces Participation in Three Upcoming Hematology Events

NEW YORK, Jan. 20, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company will be attending three upcoming events focused on hematology. Dr. David Gould, SVP, Corporate...

Read more

19 Jan

Ascent Solar Clinches Major Contract to Supply High-Voltage Superlight Thin-Film Modules for High Altitude Aerospace Application

THORNTON, CO–(Marketwired – Jan 19, 2017) – Ascent Solar Technologies, Inc. ( OTCQB : ASTI ), a developer and manufacturer of state-of-the-art, lightweight, and flexible thin-film photovoltaic (PV) solutions, announces that the Company has secured a major contract from an Asian customer to supply its high-voltage, superlight thin-film module...

Read more

19 Jan

Moleculin Announces Expanded Scientific Advisory Board

HOUSTON, TX–(Marketwired – January 19, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center,...

Read more

19 Jan

Cytori to Acquire Proprietary Nanoparticle Development Platform to Enhance Regenerative Medicine Leadership Position

SAN DIEGO, Jan. 19, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (the “Company” or “Cytori”) today announced it has entered into a definitive agreement (the “Purchase Agreement”) to acquire certain assets from privately held Azaya Therapeutics Inc., a leader in the research, development and manufacturing of nanoparticle and...

Read more

19 Jan

Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium

LAWRENCEVILLE, N.J., Jan. 19, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced that it will present two posters at the American Society of Clinical Oncology (ASCO) – Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium being held from February 23 – 25, 2017 in Orlando, FL.  The symposium...

Read more

19 Jan

SeeThruEquity Issues Update on PixarBio Corporation (OTCQX: PXRB)

NEW YORK, NY / ACCESSWIRE / December 19, 2016 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has issued an update note on PixarBio Corporation (PXRB). The report is available here: PXRB Update Note. Based in Cambridge, MA, PixarBio...

Read more

18 Jan

NABUFIT Reaches more than 510,000 Downloads of its Physical Fitness App

NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) — NABUFIT Global Inc. (NBFT), developer of a ground breaking new training portal that enhances individual workouts by providing expert advice from professional trainers, health experts and international sports stars, today announced that since it launched the NABUFIT App on July 19, 2016, there...

Read more

18 Jan

Celsion Corporation Announces Issuance of Two New Patents for ThermoDox®

LAWRENCEVILLE, N.J., Jan. 18, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN), a clinical stage oncology drug development company, today announced that the United States Patent and Trademark Office has granted U.S Utility Patent No. 9,492,385 B2 – Temperature-Sensitive Liposomal Formulation, which is directly applicable to the method of treating...

Read more

18 Jan

Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer

NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced that Dr. Mark Berger has been appointed Chief Medical Officer effective today. Dr. Berger joins Actinium with significant...

Read more

18 Jan

Aytu BioScience Announces Two Presentations Highlighting Benefits of Natesto® (Testosterone) Nasal Gel in Men at American Urological Association Annual Meeting

ENGLEWOOD, Colo., Jan. 18, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that two posters demonstrating clinical data for Natesto® (testosterone) Nasal Gel were accepted for presentation at the American Urological Association 2017...

Read more

Page 1 of 20912345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address